Combination therapy in a transgenic model of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The pathological accumulation of the β-amyloid protein (Aβ) has been closely associated with synaptic loss and neurotoxicity contributing to cognitive dysfunction in Alzheimer’s disease (AD). Oligomers of Aβ42 appear to be the most neurotoxic form. Two of the most promising attempts to reduce Aβ accumulation have been with scyllo-inositol, an inositol steroisomer, that stabilizes Aβ42 peptide and prevents it from progressing to oligomers and fibrils and R-flurbiprofen, a purified enantiomer of the classical racemic non-steroidal anti-inflammatory drugs (NSAID), flurbiprofen, that retains the ability to specifically lower Aβ42. In the present study we evaluated the effects of scyllo-inositol and the combination treatment of scyllo-inositol + R-flurbiprofen on amyloid pathology and hippocampal-dependent memory function in 5XFAD mice, a model of Aβ pathology characterized by an enormous production of Aβ42. Our expectations were that the combination treatment of scylloinositol + R-flurbiprofen would have an additive effect in preventing Aβ accumulation and that cognition would be improved. Mice treated with scyllo-inositol exhibit 41 and 35% reduction in the deposition of the amyloid plaques stained by antibody against Aβ42 and Aβ40 respectively. Scyllo-inositol was not more effective when combined with R-flurbiprofen for the measures tested. Scyllo-inositol treated mice performed significantly better at the radial arm water maze (RAWM) task than untreated and scyllo-inositol + R-flurbiprofen treated mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 4×
“5XFAD transgenic mice, developed by Oakley (Oakley et al., 2006), coexpress human APP and PS1 by combining multiple FAD mutations [APP K670N/M671L (Swedish) + I716V (Florida) + V717I (London) and PS1 M146L + L286V] with neuronal expression driven by the Thy-1 promoter were purchased from Jackson Laboratory.”
MethodInfluentialA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 3×
“…of NSAIDs against AD pathologies are observed in various experimental models and NSAIDs have been one of the therapeutic approaches for AD treatment by either delaying onset or preventing progression of AD (Eriksen et al., 2003; in t’ Veld et al., 2001; Jantzen et al., 2002; Weggen et al., 2001).”
BackgroundDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 1×
“Although multiple other complex systems are likely involved in the pathogenesis of AD, there is substantial evidence that Aβ neurotoxicity, especially nonfibrillar oligomers derived from Aβ42, is a fundamental event (Selkoe, 2004; Walsh and Selkoe, 2004).”
BackgroundNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“Many studies in both AD patients and animal models have shown that the brain levels of soluble oligomeric form of Aβ strongly correlate with senile plaques, one of the pathological hallmarks of AD (Koffie et al., 2009; Shankar et al., 2008).”
BackgroundNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · cited 3×
“…of NSAIDs against AD pathologies are observed in various experimental models and NSAIDs have been one of the therapeutic approaches for AD treatment by either delaying onset or preventing progression of AD (Eriksen et al., 2003; in t’ Veld et al., 2001; Jantzen et al., 2002; Weggen et al., 2001).”
BackgroundMethodA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 2×
“Scyllo-inositol has recently been in human clinical trials for the treatment of patients with mild to moderate AD (Salloway et al., 2011).”
Background
Cited by
Centella Asiatica Improves Memory and Promotes Antioxidative Signaling in 5XFAD Mice
Matthews, D. G., Caruso, M., Murchison, C. F., Zhu, J. Y., Wright, K. M., Harris, C. J., Gray, N. E., Quinn, J. F., & Soumyanath, A. (2019) · Antioxidants · doi:10.3390/antiox8120630 · Cited by 86
“5XFAD mice show impaired remote memory stabilization prior to four months of age [49]; impaired spatial memory in the Y-maze at 4–5 months of age [35], Morris water maze at six months of age [50,51], and radial water maze at eight months of age [52]; decreased working memory and learning during NORT testing at six mon…”
MethodPTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease
Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.020 · Cited by 64
Neuroimaging of mouse models of Alzheimer’s disease
Jullienne, A., Trinh, M. V., & Obenaus, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020305 · Cited by 32
“The authors also noted decreased NAA in the cortex, as was reported in the 5xFAD model [64,71,120].”
BackgroundResultZhou, L., Zhang, Y., Liu, R.-Y., Smolen, P., Cleary, L. J., & Byrne, J. H. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3330-14.2015 · Cited by 14
Metadata
- Authors
- Aytan, N., Choi, J.-K., Carreras, I., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 250
- Pages
- 228-238
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2012630959
- Cited by
- 36
- References
- 9
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy in a transgenic model of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.expneurol.2013.10.001
- The paper
- Aytan, N., Choi, J.-K., Carreras, I., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2013). Combination therapy in a transgenic model of Alzheimer's disease. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2013.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.